Research Article
BibTex RIS Cite

Fetal persistan supraventriküler taşikardilerin tedavisi: Tersiyer bir perinatal tıp merkezi deneyimi

Year 2019, , 1511 - 1517, 15.08.2019
https://doi.org/10.30569/adiyamansaglik.533297

Abstract

Amaç: Kliniğimizde tedavi edilen persistan fetal supraventriküler taşikardi
hastalarının sonuçlarını değerlendirmek.



Gereç ve Yöntemler: Bir buçuk yıllık dönemde fetal persistan
supraventriküler taşikardi nedeniyle tedavi edilen hastalar retrospektif olarak
değerlendirildi.
Hastaya özel tedavi ve sonuçları kaydedildi. İlaçların
etkinliği bildirildi.



Bulgular: Toplam sekiz fetal persistan supraventriküler taşikardi vakası bu
dönemde tedavi edildi.  Beş hastanın üçü
hidropik fetüslerdi. Hidrops fetalis varlığına göre tedavi için sadece digoksin
ve digoksinle kombine sotalol kullanılmıştır. Antiaritmik tedavi, toplam da sekiz
fetal persistan supraventriküler taşikardi vakasının yedisinde başarılıydı.



Sonuç: Tek başına digoksin, eğer fetal hydrops yok ise  supraventriküler taşikardi tedavisinde etkili
görünmektedir. Fetal hidrops durumunda, sotalol ilavesi iyi bir alternatif
olabilir.

References

  • 1. Macones GA, Hankins GD, Spong CY, Hauth J, Moore T. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Journal of Obstetric, Gynecologic, & Neonatal Nursing. 2008;37(5):510-5.
  • 2. Bianchi DW, Crombleholme TM, D'Alton ME, Malone F. Fetology: diagnosis and management of the fetal patient: McGraw Hill Professional; 2010.
  • 3. Hornberger LK, Sahn DJ. Rhythm abnormalities of the fetus. Heart. 2007;93(10):1294-300.
  • 4. Kleinman C, Nehgme R. Cardiac arrhythmias in the human fetus. Pediatric cardiology. 2004;25(3):234-51.
  • 5. van Engelen AD, Weijtens O, Brenner JI, Kleinman CS, Copel JA, Stoutenbeek P, et al. Management outcome and follow-up of fetal tachycardia. Journal of the American College of Cardiology. 1994;24(5):1371-5.
  • 6. Wakai R, Strasburger J, Li Z, Deal B, Gotteiner NL. Magnetocardiographic rhythm patterns at initiation and termination of fetal supraventricular tachycardia. Circulation. 2003;107(2):307-12.
  • 7. Jaeggi E, Öhman A. Fetal and neonatal arrhythmias. Clinics in perinatology. 2016;43(1):99-112.
  • 8. Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur S-AB, Rammeloo L, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011;124(16):1747-54.
  • 9. Zoeller BB. Treatment of fetal supraventricular tachycardia. Current treatment options in cardiovascular medicine. 2017;19(1):7.
  • 10. Younis JS, Granat M. Insufficient transplacental digoxin transfer in severe hydrops fetalis. American Journal of Obstetrics & Gynecology. 1987;157(5):1268-9.
  • 11. Cuneo BF, Benson DW. Use of maternal flecainide concentration in management of fetal supraventricular tachycardia: A step in the right direction. Heart rhythm. 2014;11(11):2054-5.
  • 12. Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek P, Visser GH, et al. Sotalol in the treatment of fetal dysrhythmias. Circulation. 2000;101(23):2721-6.
Year 2019, , 1511 - 1517, 15.08.2019
https://doi.org/10.30569/adiyamansaglik.533297

Abstract

References

  • 1. Macones GA, Hankins GD, Spong CY, Hauth J, Moore T. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Journal of Obstetric, Gynecologic, & Neonatal Nursing. 2008;37(5):510-5.
  • 2. Bianchi DW, Crombleholme TM, D'Alton ME, Malone F. Fetology: diagnosis and management of the fetal patient: McGraw Hill Professional; 2010.
  • 3. Hornberger LK, Sahn DJ. Rhythm abnormalities of the fetus. Heart. 2007;93(10):1294-300.
  • 4. Kleinman C, Nehgme R. Cardiac arrhythmias in the human fetus. Pediatric cardiology. 2004;25(3):234-51.
  • 5. van Engelen AD, Weijtens O, Brenner JI, Kleinman CS, Copel JA, Stoutenbeek P, et al. Management outcome and follow-up of fetal tachycardia. Journal of the American College of Cardiology. 1994;24(5):1371-5.
  • 6. Wakai R, Strasburger J, Li Z, Deal B, Gotteiner NL. Magnetocardiographic rhythm patterns at initiation and termination of fetal supraventricular tachycardia. Circulation. 2003;107(2):307-12.
  • 7. Jaeggi E, Öhman A. Fetal and neonatal arrhythmias. Clinics in perinatology. 2016;43(1):99-112.
  • 8. Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur S-AB, Rammeloo L, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011;124(16):1747-54.
  • 9. Zoeller BB. Treatment of fetal supraventricular tachycardia. Current treatment options in cardiovascular medicine. 2017;19(1):7.
  • 10. Younis JS, Granat M. Insufficient transplacental digoxin transfer in severe hydrops fetalis. American Journal of Obstetrics & Gynecology. 1987;157(5):1268-9.
  • 11. Cuneo BF, Benson DW. Use of maternal flecainide concentration in management of fetal supraventricular tachycardia: A step in the right direction. Heart rhythm. 2014;11(11):2054-5.
  • 12. Oudijk MA, Michon MM, Kleinman CS, Kapusta L, Stoutenbeek P, Visser GH, et al. Sotalol in the treatment of fetal dysrhythmias. Circulation. 2000;101(23):2721-6.
There are 12 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Research Article
Authors

Emre Ekmekçi 0000-0003-2494-3073

Servet Gençdal 0000-0002-2197-5742

Publication Date August 15, 2019
Submission Date February 27, 2019
Acceptance Date June 11, 2019
Published in Issue Year 2019

Cite

AMA Ekmekçi E, Gençdal S. Fetal persistan supraventriküler taşikardilerin tedavisi: Tersiyer bir perinatal tıp merkezi deneyimi. ADYÜ Sağlık Bilimleri Derg. August 2019;5(2):1511-1517. doi:10.30569/adiyamansaglik.533297